What is Putney?
Putney operates as a specialized pharmaceutical entity dedicated to the development and distribution of high-quality, cost-effective generic medications for companion animals. By bridging the gap between affordability and clinical efficacy, the company empowers veterinary professionals to enhance treatment compliance among pet owners. Its business model is anchored in rigorous research and development, leveraging direct feedback from the veterinary community to expand its portfolio of generic drug options. This strategic focus on the pet healthcare market positions Putney as a critical partner in the veterinary supply chain, effectively addressing the rising demand for accessible animal health solutions.
How much funding has Putney raised?
Putney has raised a total of $49.3M across 5 funding rounds:
Series A
$2.5M
Series B
$6.7M
Series C
$21M
Debt
$3M
Private Equity
$16.1M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2009): $6.7M, investors not publicly disclosed
Series C (2011): $21M supported by Safeguard Scientifics and NewSpring Capital
Debt (2014): $3M featuring NewSpring Health Capital
Private Equity (2014): $16.1M, investors not publicly disclosed
Key Investors in Putney
Safeguard Scientifics
Safeguard Scientifics is a venture capital and private equity firm that provides capital and operational expertise to fuel the growth of technology-driven businesses in healthcare, financial services, and digital media.
NewSpring Capital
NewSpring Capital partners with companies in dynamic industries to catalyze growth, working closely with management teams to develop businesses into market leaders through an extensive network of industry experts.
NewSpring Health Capital
A specialized division of NewSpring Capital, this entity focuses on healthcare-specific investments, providing the strategic guidance necessary for firms to scale within the complex medical and pharmaceutical landscape.
What's next for Putney?
With the recent infusion of capital, Putney is well-positioned to accelerate its research and development initiatives, focusing on the next generation of generic veterinary products. The company's strategic roadmap likely involves scaling its distribution networks and deepening its integration with industry partners to maintain its competitive edge. As the veterinary pharmaceutical landscape continues to consolidate, Putney's ability to leverage its existing financial backing will be instrumental in navigating market shifts and sustaining its commitment to providing affordable, high-standard medicine for the companion animal market.
See full Putney company page
